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EDRF role in renal function and blood pressure of normal rats and rats
with obstructive uropathy. There is a decrease in glomerular filtration
rate (GFR) and effective renal plasma flow (ERPF) and an increase in
mean arterial pressure (MAP) and renal vascular resistance (RVR) after
release of bilateral ureteral obstruction (BUO) of 24 hours duration. The
present studies examine the role of endothelium-derived relaxing factor
(EDRF) in the renal hemodynamics of sham-operated rats (SOR) and
rats in which BUO of 24 hours duration was unilaterally released. In
both groups of rats, renal function and blood pressure were measured in
the awake state under basal conditions and after administration of
L-arginine (L-arg), the substrate for EDRF synthesis, followed by
NWNAME, an L-arg antagonist, or after administration of NWNAME
followed by L-arg. Administration of L-arg alone to SOR did not affect
renal function, MAP or RVR. In SOR given L-arg and then NWNAME,
there was significantly decreased GFR and ERPF and increased MAP
and RVR. When NWNAME was given initially, similar changes were
obtained, and these were reversed by the administration of L-arg. Rats
given L-arginine immediately after unilateral release of BUO of 24
hours duration had significantly greater GFR and ERPF values and
lower MAP and RVR than temporal controls. NWNAME given to BUO
rats decreased renal function further and increased MAP and RVR. We
found a dose-dependent increase in GFR and ERPF and a dose-
dependent decrease in MAP and RVR in both SOR and rats with BUO
given increasing amounts of L-arg. There was also a dose-dependent
decrease in GFR and ERPF and an increase in MAP and RVR in SOR
and rats with BUO given increasing amounts of NWNAME or N°NMA,
the two different antagonists of L-arg. In another set of experiments,
SOR and rats with BUO were given L-arg preoperatively (that is, 24 hr
prior to study). Both groups of rats had significantly higher GFR and
ERPF values and lower MAP and RVR than control rats. Sham-
operated rats given NWNAME 24 hours prior to study had significantly
lower GFR and ERPF and higher MAP and RVR than untreated rats.
Rats with BUO given NWNAME prior to obstruction had no measurable
renal function and had significantly higher values for MAP after release
of obstruction. These studies confirm the role of L-arg administration,
and presumably EDRF, in the regulation of MAP and renal function in
sham-operated rats. The results of this study also suggest decreased
availability of arginine for EDRF synthesis in rats with BUO. We
suggest that decreased EDRF activity has a role in the renal hemody-
namic changes seen following ureteral obstruction.
After unilateral release of bilateral ureteral obstruction
(BUO) of 24 hours duration, an increase in renal vascular
resistance is present that may account, at least in part, for the
marked decrease in glomerular filtration rate (GFR) and effec-
tive renal plasma flow (ERPF) observed in this setting 11]. The
role of several vasoconstrictors and vasodilators in the changes
in renal hemodynamics observed during obstruction has been
studied in this and other laboratories. Angiotensin II [2],
thromboxane A2 [3], and antidiuretic hormone [4] decrease
GFR and ERPF, whereas prostaglandins [5] and platelet-acti-
vating factor (PAF) [6] tend to maintain GFR and ERPF.
Inhibiting the synthesis of vasoconstrictors such as angiotensin
II [2] or thromboxane A2 [3], or administering a specific
V1-receptor antagonist of antidiuretic hormone [4] or picomolar
amounts of PAF in the setting of prior inhibition of TxA2
synthesis, significantly increases GFR and ERPF after unilat-
eral release of BUO of 24 hours duration, but not to normal
values. This suggests increased activity of other vasoconstric-
tor(s) and/or decreased activity of other vasodilator(s) in this
setting. Among the latter, the role of endothelium-derived
relaxing factor (EDRF) in the hemodynamic changes seen in
BUO has not been examined.
EDRF is produced by endothelial cells after stimulation with
acetyicholine [7] or bradykinin [81. Nitric oxide (NO), or a
closely related substance, accounts for the biological activity of
EDRF [9]. The guanidino nitrogens of the amino acid L-arginine
are the source of the NO generated after stimulation of porcine
endothelial cells in culture with bradykinin [10]. Nitric oxide
synthetase, the enzyme responsible for NO synthesis from
L-arginine, is a calcium- and NADPH-dependent enzyme which
is stimulated by calmodulin [11]. Studies have also demon-
strated that the EDRF system promotes the conversion of GTP
to cyclic GMP [12] by activation of the soluble heme fraction of
guanylate cyclase [13]. Increased concentrations of cGMP
decrease intracellular levels of calcium and lead to relaxation of
smooth muscle cells [14]. The amino acid L-arginine is synthe-
sized from citrulline [15] and cortical tubules are the most active
site of its synthesis within the kidney [161. The above studies
suggest a central role for the kidney in the modulation of this
newly described biological system.
The present study examines the role of EDRF in renal
function and the regulation of mean arterial pressure of normal
rats and rats with unilateral release of BUO of 24 hours
duration.
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Methods
Animals and chemicals
Female Sprague-Dawley rats weighing 170 to 233 g (mean 195
2.2 g) were obtained from Sasco Inc. (Omaha, Nebraska,
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USA). After arrival the animals were housed five or six to a
cage, were fed a standard rat chow containing 22.8% protein
(Ralston Purina, St. Louis, Missouri, USA) and had water ad
libitum. No experiments were performed earlier than seven
days after arrival of the animals.
Inulin, L-arginine, N''-nitro-l-arginine methyl ester
(NWNAME) and N°-methylarginine (N°NMA) were purchased
from Sigma Chemical Co. (St. Louis, Missouri, USA). PAH
was purchased from Merck, Sharp & Dohme (West Point,
Pennsylvania, USA). The L-arginine inhibitors used in this
study, NWNAME and NGNMA, are selective competitors of
L-arginine for the enzyme EDRF/NO synthase.
Bilateral ureteral obstruction
BUO was performed in 54 rats under light ether anesthesia by
ligating both ureters at the junction of their lower one third and
upper two thirds through a small suprapubic incision. The rats
were returned to their cages and were not allowed food or
water. They were studied 24 hours later. Sham operation was
performed in 48 rats under light ether anesthesia. The abdom-
inal cavity was opened and both ureters were manipulated but
not ligated. Rats were returned to their cages and were studied
24 hours later.
Clearance studies and blood pressure deter,ninations
Standard clearance studies were performed as previously
described [2]. Briefly, under light ether anesthesia, a left
femoral artery catheter (PE-SO), and a left femoral vein catheter
(PE-lO) were inserted. In rats with BUO unilateral release of
the obstruction was accomplished by inserting a catheter (PE-
10) above the ligature of the left ureter. In sham-operated rats
(SOR) a bladder catheter (Tygon®) was inserted. The rats were
secured in plastic holders and two hours after recovery from
anesthesia were studied in the awake state. A priming dose of
inulin designed to produce plasma levels of 70 to 150 mg/dl and
PAH calculated to produce plasma levels of 1 to 2 mgldl was
administered in 0.6 ml of normal saline (NS) over a three minute
period. This was followed by a sustained infusion delivered at
40 p1/mm, which contained sufficient inulin and PAH to main-
tain plasma levels of these compounds constant. After an
equilibration period of at least 60 minutes, two consecutive
20-minute collections of urine and blood were obtained for
estimation of GFR by inulin clearance (C1,,) and effective renal
plasma flow (ERPF) by para-aminohippuric acid (PAH) clear-
ance (CPAu). A second set of two 20-minute clearance collec-
tions was obtained five minutes after an i.v. bolus infusion of
normal saline (NS), L-arginine or N"-nitro-L-arginine methyl
ester (NWNAME), a specific antagonist of L-arginine, as de-
scribed below. A third set of two 20-minute clearance collec-
tions was obtained five minutes after an i.v. bolus of NS,
L-arginine or NWNAME, the L-arginine antagonist, as de-
scribed below, and in some experiments a fourth set of clear-
ance collections was obtained in a like manner. Mean arterial
pressure (MAP) was measured throughout the study using the
remoral artery catheter connected to a Harvard Apparatus
(WECO VT- 1, Winston Electronics Co, Millbrae, California,
USA).
Experimental groups
Twenty groups of rats were studied (Table 1). The clearance
protocols used in the different groups of rats are shown in
Figure 1. In addition, some groups of SOR or BUO rats were
Table 1. Different groups of rats studied
N
5 Sham-operated rats given saline (protocol 1)
5 Sham-operated rats given L-arginine, N"-NAME
(protocol 2)
3 5 Sham-operated rats given N"-NAME, L-arginine
(protocol 3)
4 5 BUO rats given saline (protocol 1)
5 7 BUO rats given L-arginine, NWNAME (protocol
2)
6 8 BUO rats given NWNAME, L-arginine (protocol
3)
7 7 Sham-operated rats given I ml of normal saline 24
hr prior to clearance studies
8 5 Sham-operated rats given L-arginine in the
drinking water for 2 days prior to study and
intraperitoneal arginine at the time of sham-
operation
9 5 Sham-operated rats given intraperitoneal N"-
NAME 24 hr prior to study
10 5 BUO rats given 1 ml of normal saline 24 hr prior
to clearance studies
11 7 BUO rats given L-arginine in the drinking water
for 2 days prior to study and intraperitonal
arginine at the time of ureteral ligation
12 8 BUO rats given intraperitoneal N''-NAME 24 hr
prior to study
13 4 Sham-operated rats given 4 i,v. bolus injections
of 1 ml of normal saline (protocol 4)
14 4 BUO rats given 4 i.v. bolus injections of 1 ml of
normal saline (protocol 4)
15 5 Sham-operated rats given i.v. bolus of increasing
amounts of arginine (protocol 5)
16 4 BUO rats given iv, bolus of increasing amounts
of L-arginine (protocol 5)
17 4 Sham-operated rats given iv. bolus of increasing
amounts of N"-NAME (protocol 6)
18 4 BUO rats given i.v. bolus of increasing amounts
of N""-NAME (protocol 6)
19 3 Sham-operated rats given iv. bolus of increasing
amounts of NENAME (protocol 7)
20 2 BUO rats given i.v. bolus of increasing amounts
of NENAME (protocol 7)
pretreated with L-arginine or NWNAME for 24 or 48 hours
before clearance studies.
Effect of bolus ad,ninistration of normal saline or L-arginine
followed by N"NAME or N"NAME followed by L-arginine on
renal function of SOR (Groups 1—3) and rats with BUO (Groups
4—6). These experiments were performed using protocols 1 to 3
(Fig. 1). Group 1 consisted of five SOR and Group 4 consisted
of five rats with BUO. These two groups served as temporal
controls. After the first set of two 20-minute clearance studies
were performed these rats received an i.v. bolus of 1 ml of NS
over a one minute period, and after five minutes two additional
20-minute clearance determinations were obtained. Thereafter,
another i.v. bolus of 1 ml of NS was administered over a one
minute period and the last two 20-minute clearance collections
were obtained (protocol 1, Fig. 1).
Group 2 consisted of five SOR and Group 5 consisted of
seven rats with BUO. After basal studies, these rats received an
i.v. bolus of L-arginine (300 mg/kg body wt) in 1 ml of NS over
a one minute period, and five minutes later two additional
20-minute clearance determinations were obtained. Subse-
quently, these rats received an i.v. bolus of NWNAME (200
Group
2
Description
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Clearance protocols
First Second Third
set set set
Protocol 1 F NS L NS NS
Protocol 2 NS L-arg NWNAME
Protocol 3 NS NWNAME L-arg 1
ProtocoI4
NS NS 1 NS NS
Protocol 5 NS 1/2 L-arg L-arg 2 L-arg
Protocol 6 NS J 1/2 NWNAME NWNAME [ 2 NWNAME
Protocol 7 NS 1/2 N°NMA NNMA
j.g/kg body wt) dissolved in I ml of NS over a one minute
period, and after five minutes a third set of clearance collections
was obtained (protocol 2, Fig. 1).
Group 3 consisted of five SOR and Group 6 consisted of eight
rats with BUO. After basal studies, these rats received an i.v.
bolus of NWNAME (200 igJkg body wt) in 1 ml of NS over a one
minute period and after five minutes a second set of two
20-minute collections was obtained. Subsequently, these rats
received an i.v. bolus of L-arginine (300 mg/kg body wt) in 1 ml
Fig. 1. Protocols used during physiological
studies in sham operated rats or rats with
BUO. In each protocol rats were given inulin
and PAH throughout to measure glomerular
filtration rate and effective renal plasma flow.
Protocol 1 (Groups I and 4). A first set of two
20-minute clearance periods was obtained
during normal saline (NS) infusion, then an
i.v. bolus of 1 ml of NS was given and 5
minutes later two additional 20-minute periods
were obtained. After a subsequent i.v. bolus
of I ml of NS, a third set of two 20-minute
clearance collections was obtained. Protocol 2
(Groups 2 and 5). This consisted of a first set
of two 20-minute clearance periods during NS
Fourth infusion followed by a bolus injection of L-
set arginine (300 mg/kg body wt) dissolved in I ml
of NS and 5 minutes later two additional 20-
minute clearance periods were obtained.
Subsequently, the rats received NWNAME, an
antagonist of L-arginine (200 pg/kg body wt)
dissolved in 1 ml of NS and 5 minutes later a
third set of two 20-minute clearance
collections was obtained. Protocol 3 (Groups
3 and 6). This consisted of a first set of two
20-minute clearance periods during NS
infusion, followed by an i.v. bolus of
NWNAME (200 tg/kg body wt) dissolved in 1
ml of NS; 5 minutes later a second set of two
20-minute clearance measurements was
obtained. Subsequently, the rats received an
i.v. bolus of L-arginine (300 mg/kg body wt)
and 5 minutes later an additional two 20-
minute clearance collections were obtained.
Protocol 4 (Groups 13 and 14). This consisted
of four consecutive sets of two 20-minute
clearance periods following an i.v. bolus of 1
ml of normal saline. Protocol 5 (Groups 15
and 16). This consisted of progressive
_______________
increases in the amount of L-arginine given as
a bolus: 1/2 L-arg, 150 mg/kg body wt; L-arg,
300 mg/kg body wt, and 2 L-arg 600 mg/kg
body wt. A set of two 20-minute clearance
collections was obtained after each of the
different doses was given. Protocol 6 (Groups
17 and 18). This consisted of progressive
______________ increases in the amount of NWNAME given as
a bolus: 1/2 NWNAME, 100 pg/kg body wt;
NWNAME, 200 pg/kg body wt; and 2
NWNAME, 400 pg/kg body wt. A set of two
_______________
20-minute clearance collections was obtained
after each of the different doses was given.
Protocol 7 (Groups 19 and 20). This consisted
of progressive increases in the amount of
N°NMA given as a bolus: 1/2 N°NMA, 15
mg/kg body wt; N°NMA, 30 mg/kg body wt;
_____________
and 2 N°NMA, 60 mg/kg body wt. A set of
two 20-minute clearance collections was
2 N°NMA obtained after each of the different doses was
given.
of NS over a one minute period, and after five minutes two
additional 20-minute clearance collections were obtained (pro-
tocol 3, Fig. 1).
Effect of pretreatment with L-arginine or N'NAME 24 hours
prior to studies of renal function in SOR (Groups 7—9) and rats
with BUO (Groups 10—12). These experiments were performed
in rats from groups 7 through 12. Groups 7 (SOR, N = 7) and 10
(rats with BUO, N = 5) were pretreated with 1 ml of NS 24
hours prior to clearance studies. Groups 8 (SOR, N = 5) and 11
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Fig. 2. Values for mean arterial blood
pressure (MAP) and renal vascular resistance
(RVR) in 3 groups of sham-operated rats and
3 groups of rats with bilateral ureteral
obstruction. Groups of rats shown were
studied according to the protocols described
in Figure 1, as follows: (U) protocol I (saline
throughout); (0) protocol 2 (arginine, followed
by N"NAME); (D) protocol 3 (NWNAME
followed by L-arginine). Characterization of
groups by protocol is given in the text.
* Significantly different (P <0.05) from
baseline values of the same group.
(rats with BUO, N = 7) were pretreated with L-arginine 0.1%
solution added to the drinking water for two days prior to
studies and one i.p. dose of L-arginine (300 mg/kg body wt)
dissolved in 1 ml of NS given at the time of BUO or sham
operation. These rats received a similar dose of L-arginine 12
hours prior to clearance studies. Groups 9 (SOR, N = 5) and 12
(rats with BUO, N = 8) were given an i.p. dose of NWNAME
(200 pg/kg body wt) dissolved in 1 ml of NS 24 hours prior to
studies.
Dose-response effects of L-arginine and two of its selective
antagonists on renal function and MAP and R VR of SOR and
rats with BUO. These experiments were performed in rats from
groups 13 through 20 according to the protocols described in
Figure 1 using NWNAME and NGnitromethylLarginine
(N°NMA). These experiments were also used to obtain mea-
surements of the excretion of cGMP in the urine. The procedure
was as follows: after two 20-minute baseline clearance collec-
tions, rats from Group 13 (sham operated, N = 4) and Group 14(rats with BUO, N = 4) received four sequential i.v. bolus
injections of 1 ml of NS, with a new set of two 20-minute
clearance collections obtained after each administration of NS
(protocol 4, Fig. 1).
In rats from groups 15 (SOR, N = 5) and 16 (rats with BUO,
N = 4) two 20-minute baseline clearance collections were
obtained. Subsequently, these rats received an i.v. bolus of
increasing doses of L-arginine (150, 300 and 600 mg/kg body wt)
dissolved in 1 ml of NS over a one minute period with two
20-minute clearance period collections obtained after each
increase in the dose of L-arginine (protocol 5, Fig. 1).
In rats from groups 17 (SOR, N = 4) and 18 (rats with BUO,N = 4) two 20-minute baseline clearance collections were
obtained. Subsequently, these rats received an i.v. bolus of
increasing doses of NWNAME (100, 200 and 400 jsg/kg body wt)
dissolved in 1 ml of NS over a one minute period with two
20-minute clearance period collections obtained after each
increase in the dose of NWNAME (protocol 6, Fig. 1).
In rats from groups 19 (SOR, N = 3) and 20 (rats with BUO,
N = 2), two 20-minute baseline clearance collections were
obtained. Subsequently, these rats received an i.v. bolus of
increasing doses of NGNMA (7.5, 15,0 and 30.0 mg/kg body wt)
dissolved in I ml of NS over a one minute period, with two
20-mm clearance period collections obtained after each increase
in the dose of NGNMA (protocol 7, Fig. 1).
Analytic determinations
Inulin was determined using the anthrone method [17] and
PAH was measured by a modification of the method of Smith et
a! [18]. The determination of cyclic GMP in urine samples was
done using a radioimmunoassay as described previously [19].
Calculations and statistics
Inulin and PAH clearances were calculated using standard
formulas. For each rat the values obtained for two clearance
periods after each experimental condition were averaged. Val-
ues for the different measurements of renal function obtained in
normal rats are expressed for one kidney. Renal vascular
resistance (RVR) was calculated according to the formula RVR
= MAP/RBF, where MAP is mean arterial pressure and RBF is
renal blood flow calculated as ERPF/1 — (17t), A paired
1-test was used for comparisons of specific determinations
within the same group of rats. Intergroup comparisons were
performed by analysis of variance (ANOVA). Differences were
considered significant when P was <0.05.
Results
The values for MAP and RVR in SOR (Groups 1 through 3)
and rats with BUO (Groups 4 through 6) subjected to protocols
1 through 3 are shown in Figure 2. Rats with BUO (Groups 4
through 6) had significantly higher basal values for MAP and
RVR than SOR. In rats from Groups 1 or 4 (protocol 1)
receiving NS only, there were no significant changes in either
MAP or RVR as a function of time. In SOR (Group 2),
administration of L-arginine did not significantly affect MAP or
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Table 2. Glomerular filtrate rate and effective renal plasma flow in
six groups of rats
GFR ERPF
mi/mm/kg body wt
Sham operated rats
Group 1 (Protocol 1)
NS 6.6 0.6 26.4 3.3
NS 6.3 0.8 26.0 0.4
NS 6.7 0.9 24.4 4.7
Group 2 (Protocol 2)
NS 7.0 0.1 27.5 1.2
L-arg 6.7 0.4 24.6 2.1
NWNAME 5.3 0.6k 14.4 3.0
Group 3 (Protocol 3)
NS 6.6 0.2 22.5 1.0
Nw.NAME 5.2 0.6 13.7 2.5a
L-arg 7.2 0.5 25.2 1.9
Rats with bilateral ureteral obstruction
Group 4 (Protocol 1)
NS 1.42 0.1 4.06 0.6
NS 1.47 0.1 3.95 0.6
NS 1.39 0.2 4.21 0.7
Group 5 (Protocol 2)
NS 1.67 0.1 4.42 0.6
L-arg 2.21 0.la 5.57 0.6
N''-NAME 1.41 0.2 3.49 0.7
Group 6 (Protocol 3)
NS 1.84 0.1 4.81 0.5
NWNAME 1.27 o.la 3.06 0.4
L-arg 1.64 0.1 4.22 0.4
Each set of measurements is the average of two 20-minute clearance
periods. Values are mean standard error of the mean. Composition of
the groups and administration of the substances is indicated in Figure 1
and Table 1. Abbreviations are: GFR, glomerular filtration rate; ERPF,
effective renal plasma flow; NS, normal saline.
a p < 0.05 when compared to basal values obtained during adminis-
tration of normal saline within the same group
RVR when compared to basal values. Subsequent administra-
tion of NWNAME, an L-arginine antagonist, resulted in an
immediate, significant and long-lasting increase in MAP and
RVR when compared to basal measurements. In BUO rats
(Group 5), administration of L-arginine (protocol 2) significantly
decreased MAP and RVR when compared to basal measure-
ments. Subsequent administration of NWNAME increased both
MAP and RVR to values not significantly different from base-
line measurements. In SOR (Group 3) and BUO rats (Group 6),
administration of NWNAME (protocol 3) significantly increased
MAP and RVR when compared to basal values. Subsequent
administration of L-arginine to these rats decreased MAP and
RVR to near baseline levels in both groups.
The values for GFR, as measured by C1, and ERPF, as
measured by CPAH, in SOR (Groups ito 3), and rats with BUO
(Groups 4 to 6) are summarized in Table 2. There were no
significant changes in either GFR or ERPF as a function of time
in SOR given saline throughout (Group 1, protocol 1). There
was also no significant change in GFR or ERPF in SOR after
administration of L-arginine (Group 2, protocol 2) when com-
pared to basal values. Subsequent administration of NWNAME
significantly decreased GFR and ERPF in this group of rats.
Administration of NWNAME to SOR (Group 3, protocol 3)
significantly decreased GFR and ERPF when compared to basal
values. Subsequent administration of L-arginine to this group of
rats increased GFR and ERPF to values not significantly
different from basal values.
Rats with BUO (Groups 4 to 6, Table 2) had GFR and ERPF
values that were about 20 to 25% and 15 to 20%, respectively,
of the values obtained for one kidney in SOR. There was no
significant change in either GFR or ERPF as a function of time
in BUO rats given saline throughout (Group 4). In rats of Group
5, administration of L-arginine significantly increased GFR and
ERPF when compared to basal values. Subsequent administra-
tion of NWNAME decreased GFR and ERPF to values lower
than, but not significantly different from, those observed under
basal conditions. In rats of Group 6, administration of
NWNAME significantly decreased GFR and ERPF when com-
pared to basal values. Subsequent administration of L-arginine
significantly increased GFR and ERPF to values not signifi-
cantly different from those seen under basal conditions.
Figure 3 shows the absolute changes in GFR and ERPF in the
different groups of SOR and rats with BUO. There were no
significant changes in either GFR or ERPF in SOR (Group 1) or
BUO rats (Group 4) given NS throughout (protocol 1). SOR
(Group 2) given L-arginine had no significant changes in GFR or
ERPF compared to basal values. Subsequent administration of
NWNAME (protocol 2) to these rats significantly decreased
GFR by 1.7 mI/mm/kg body wt and ERPF by 13.1 mllmin/kg
body wt, compared to basal values. Administration of
NWNAME to SOR (Group 3) significantly decreased GFR by
1.4 ml/min/kg body wt and ERPF by 8.8 mllmin/kg body wt.
Subsequent administration of L-arginine increased GFR and
ERPF to values greater than, but not significantly different
from, those observed under basal conditions (a difference from
basal values of 0.6 and 2.7 ml/minfkg body wt, respectively;
protocol 3). In BUO rats (Group 5) administration of L-arginine
significantly increased GFR by 0.54 mllmin/kg body wt and
ERPF by 1.15 mI/mm/kg body wt. Subsequent administration of
NWNAME decreased GFR and ERPF to values lower than, but
not significantly different from, those obtained under basal
conditions (a difference of 0.26 and 0.93 mI/mm/kg body wt,
respectively; protocol 2). Administration of NWNAME to BUO
rats (Group 6) significantly decreased GFR by 0.57 mllmin/kg
body wt, and ERPF by 1.75 mllmin/kg body wt, when compared
to values obtained under basal conditions. Subsequent admin-
istration of L-arginine to these rats increased GFR and ERPF to
values lower than, but not significantly different from, those
obtained under basal conditions (a difference of 0.20 and 0.59
ml/minlkg body wt, respectively; protocol 3).
Figure 4 presents the values for MAP and RVR in rats from
Groups 7 through 12. Sham operated rats pretreated with
L-arginine (Group 8) prior to studies had values for MAP that
were not significantly different from those obtained in control
SOR given normal saline alone (Group 7). However, SOR given
L-arginine (Group 8) had significantly lower values for RVR.
SOR pretreated with NWNAME (Group 9) had significantly
higher MAP and RVR than control SOR from Group 7. Rats
with BUO pretreated with L-arginine 24 hours prior to experi-
ments (Group 11) had significantly lower values for MAP and
RVR than rats with BUO given saline alone (Group 10). In these
rats with BUO, values for RVR, but not MAP, were signifi-
cantly higher than those obtained in SOR controls (P < 0.001).
Rats with BUO pretreated with NWNAME prior to obstruction
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Fig. 4. Values for mean arterial blood
pressure (MAP) and renal vascular resistance
(RVR) in 3 groups of sham operated rats and
3 groups of rats with bilateral ureteral
obstruction (BUO). Rats were pretreated with
normal saline, L-arginine (0.1% drinking
solution prepared in the drinking water plus 2
doses of 300 mg/kg body wt) or NWNAME
(200 pg/kg body wt) immediately prior to
studies. Rats with BUO given NWNAME were
ND anuric at the time of studies; thus, ERPF and
______ RVR values could not be calculated. ND, not
determined. * Significantly different from
values obtained in rats given saline.
(Group 12) had significantly higher MAP than BUO controls than BUO controls given saline (Group 10). Rats with BUO
(Group 10).
Figure 5 summarizes the values for GFR and ERPF in rats of
Groups 7 through 12. SOR pretreated with L-arginirie prior to
study (Group 8) had significantly greater GFR and ERPF values
than SOR given saline alone (Group 7). SOR pretreated with
NWNAME prior to studies (Group 9) had significantly lower
GFR and ERPF values than control SOR given only saline
(Group 7). Rats with BUO pre-treated with L-arginine prior to
and during the period of obstruction (Group 11) had signifi-
cantly higher values for GFR (2.79 0.1 mI/mm/kg body wt, P
<0.05) and ERPF (8.88 0.9 mi/mm/kg body wt, P < 0.05)
pre-treated with NWNAME (Group 12) had no urine flow after
unilateral release of ureteral obstruction of 24 hours duration,
and renal function was considered as non-existent.
The effects of administering increasing doses of L-arginine,
NWNAME or NGNMA on MAP and RVR are shown in Figure
6, and renal function (Fig. 7) in SOR and rats with BUO. There
were no significant changes in MAP or RVR as a function of
time in either SOR (Group 13) or rats with BUO (Group 14) than
received normal saline and served as temporal controls. Ad-
ministration of increasing amounts of L-arginine to SOR (Group
15) resulted in slight but not significant increases in MAP
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Fig. 3. Changes in glomerular filtration rate
(GFR) and effective renal plasma flow (ERPF)
from baseline values in six groups of rats.
Groups of rats represented were studied
according to the protocols described in Figure
1, as follows: (U) protocol 1; (0) protocol 2;
(Li) protocol 3. Characterization of groups by
protocol is given in the text. * Significantly
different from values obtained in rats in
protocol I (U).
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Fig. 5. Values for glomerular filtration rate
(GFR) and effective renal plasma flow (ERPF)
in 3 groups of sham operated rats and 3
groups of rats with bilateral ureteral
obstruction (BUO). Rats were pretreated with
normal saline, L-arginine (0.1% drinking
solution prepared in the tap water plus 2
doses of 300 mg/kg body wt) or NWNAME
(200 zgfkg body wt) prior to studies. Rats
with BUO given NWNAME were anuric at the
time of studies; thus, ERPF and GFR values
could not be calculated. ND, not determined.
* Significantly different from values obtained
in control rats.
without changes in RVR. In contrast, the administration of
increasing amounts of L-arginine to rats with BUO resulted in
dose-dependent decreases in MAP and RVR (Fig. 6). Bolus
administration of increasing doses of specific but unrelated
antagonists of L-arginine to SOR (Groups 17 and 19) or rats
with BUO (Groups 18 and 20) resulted in consistent and
significant increases in MAP and RVR (Fig. 6).
In SOR the administration of increasing doses of L-arginine
(Group 15) produced a slight but significant increase in ERPF.
GFR increased, then decreased. This may be related to the dose
used and may explain the lack of effect seen in the SOR that
received arginine (300 mg/kg body wt) depicted in Table 2
(Group 2, protocol 2). In rats with BUO the administration of
increasing doses of L-arginine induced a consistent and dose-
dependent increase in GFR. However, ERPF increased initially
and then leveled off (Fig. 7). Administration of increasing doses
of NWNAME or NGNMA, specific L-arginine antagonists, to
sham operated rats (Groups 17 and 19) or rats with BUO
(Groups 18 and 20) resulted in significant and dose-dependent
decreases in renal function, as assessed by GFR and ERPF
determinations (Fig. 7).
Table 3 summarizes the values for cyclic GMP excretion in
the urine, normalized per milliliter of GFR in rats from Groups
12 through 18. As a group, rats with BUO had significantly
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Table 3. Excretion of cyclic GMP in the urine of sham-operated rats
and rats after unilateral release of BUO
Groups of rats
Cyclic GMP
pmols/min/ml C1,, P value
SOR given normal saline (N = 12)
SOR given L-arginine (N = 15)
0.79 0.19
2.81 0.44 <0.0001
BUO rats given normal saline (N = 16)
BUO rats given L-arginine (N = 12)
BUO rats given N"-NAME (N = 12)
2.24 0.38
7.90 1.28
1.81 0.56
<0.0001
Results are expressed as mean standard error of the mean.
Statistics (unpaired t-test) are:
SOR given normal saline (N = 12) vs. BUO rats given normal saline(N = 16),P < 0.002; SOR given L-arginine (N = 15) vs. BUO rats given
L-arginine (N = 12), P < 0.001; BUO given normal saline (N = 16) vs.
BUO given NWNAME (N = 12), P < 0.53.
Abbreviations are: SOR, sham operated rats; BUO, bilateral ureteral
obstruction.
higher urine excretion of cyclic GMP than SOR. SOR or rats
with BUO given arginine had significantly greater excretion
rates of cyclic GMP than SOR or rats with BUO given saline
(Table 3).
Discussion
The results of this study demonstrate that endothelium-
derived relaxing factor (EDRF) modulates basal arterial blood
pressure, renal vascular resistance, GFR and effective renal
plasma flow in normal rats and in rats with unilateral release of
BUO of 24 hours duration.
Administration of L-arginine, the substrate for EDRF, to
SOR produced significant increases in GFR and ERPF and a
significant decrease in renal vascular resistance in two of three
groups of sham operated rats treated in this fashion. These
findings are not surprising since previous reports indicate a lack
of a vasodilatory effect in response to an amino acid load when
a competitive inhibitor of L-arginine is administered [20]. Also,
a vasodilatory effect on the renal circulation has been reported
after an i.v. infusion of L-arginine [211. It should be pointed out
that high protein diets [22] or the infusion of other amino acids
[23—251 also cause a vasodilatory response in the renal circula-
tion. Although the vasodilatory response to infusion of amino
acids may be mediated by "other" mechanisms, the response
to L-arginine appears to be mediated by EDRF. Part of the
vasodilatory response to the administration of an amino acid
mixture may be mediated in part by EDRF since arginine is a
frequent component of such mixtures and is present in high
protein meals. It has been reported that the vasodilatory effect
of L-arginine is inhibited by indomethacin [26]. This would
suggest participation of a metabolite of the cyclooxygenase
pathway in this response. It is possible that the effects of
L-arginine administration observed in these studies relate not
only to increased production of EDRF but also to other
mechanisms. However, several lines of evidence suggest a
participation of the EDRF system in the vasodilatory response
observed.
In SOR, administration of two different competitive inhibi-
tors of L-arginine resulted in an immediate and significant
dose-dependent increase in both arterial blood pressure and
renal vascular resistance, and a decrease in renal function as
measured by GFR and ERPF. These effects were present when
rats were pretreated with one of the antagonists for 24 hours
before clearance studies and also when animals were not given
the antagonist until 24 hours after operation. When the antag-
onists were given acutely, effects were observed as early as five
minutes after a single i.v. bolus administration of the com-
pound. This rapid response was very likely due to decreased
production of EDRF. Thus, it appears that a sustained basal
production of EDRF is necessary to maintain normal vascular
tone under resting conditions. Subsequent administration of
L-arginine to rats previously given NWNAME as a bolus (Group
3) decreased arterial blood pressure and renal vascular resis-
tance and increased GFR and ERPF to values comparable to
those seen under basal conditions.
The inhibition of EDRF using antagonists of the endogenous
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L-arginine effect on blood pressure has been reported in anes-
thetized rabbits [27], rats [281, and guinea pigs [29]. Rees,
Palmer and Moncada [27] and Aisaka et a! [29] reported a
significant increase in arterial blood pressure after administra-
tion of N''nitro-L-arginine (L-NMMA) to rabbits and guinea
pigs, respectively. Tolins et al [28] reported an increase in
systemic blood pressure after administration of NGmethylL
arginine, another antagonist of L-arginine. This effect was
blunted after administration of L-arginine, However, the inves-
tigators did not find significant changes in either GFR or ERPF.
There are some differences between our study and that of
Tolins et al [28]. First, we observed a decrease in GFR and
ERPF and an increase in blood pressure and renal vascular
resistance after the administration of NGNMA, the same antag-
onist used by Tolins et al [28], and also after the administration
of NWNAME, a different and more potent antagonist of L-argi-
nine [30]. Also, our experiments were performed in awake
animals, a state in which cardiovascular reflexes are not altered
by anesthesia. Our findings of a decrease in GFR and ERPF and
an increase in blood pressure and renal vascular resistance after
administration of L-arginine antagonists to normal rats are
similar to those recently reported by Baylis, Harton and Engels
[21]. A recent publication [31] reports a marked effect of
L-NMMA on the glomerular circulation. Administration of this
L-arginine antagonist produced glomerular arteriolar vasocon-
striction, glomerular hypoperfusion and decreased the ultrafil-
tration coefficient (Kf).
Our studies in rats after unilateral release of BUO of 24 hours
duration confirmed the dramatic decrease in GFR and ERPF
and the marked increase in arterial blood pressure observed
previously in this model of acute renal failure [1—3]. In rats with
BUO, bolus administration of NWNAME (Group 6, protocol 3)
further decreased renal function, indicating a sustained basal
release of EDRF that counteracts the effects of the vasocon-
strictors angiotensin II [2], thromboxane A2 [3] and antidiuretic
hormone [4], which tend to decrease GFR and ERPF. This
decrease in renal function was accompanied by further in-
creases in arterial blood pressure and renal vascular resistance.
In this group of rats, subsequent administration of L-arginine
significantly increased GFR and ERPF and decreased arterial
blood pressure and renal vascular resistance. The decrease in
renal function and the increase in blood pressure and renal
vascular resistance observed after administration of the antag-
onists of L-arginine were dose-dependent.
Bolus administration of L-arginine to rats with BUO (Group
5, protocol 2), or pretreatment with L-arginine for 24 hours
prior to study (Group 11), significantly decreased both arterial
blood pressure and renal vascular resistance and increased
GFR and ERPF in these rats. Subsequent administration of an
antagonist of L-arginine (Group 5) led to increases in blood
pressure and renal vascular resistance and decreases in GFR
and ERPF to values comparable to those observed under basal
conditions. These results suggest that during the period of
obstruction there is either an alteration in the synthesis of
L-arginine or increased utilization of it, resulting in a decrease
in the serum levels of this substrate for EDRF synthesis.
Indeed, preliminary studies done in collaboration with Dr. Irene
Karl (Division of Endocrinology and Metabolism, at Washing-
ton University) reveal a significant reduction in plasma levels of
L-arginine (to about one third) in rats obstructed for 24 hours
when compared to serum values prior to obstruction or values
obtained in sham-operated rats. The hemodynamic effects
observed after arginine administration suggest that the steps
involved in the synthesis of EDRF in endothelial cells are very
likely intact after ureteral obstruction of 24 hours duration.
The exact mechanism by which BUO decreases the circulat-
ing levels of L-arginine cannot be elucidated from the present
experiments. However, it is tempting to speculate that de-
creased renal function plays a central role. It has been known
for a number of years that the kidney synthesizes L-arginine
from citrulline [15]. The enzyme arginino succinase converts
citrulline to L-arginine by transferring a nitrogen from aspar-
tate, glutamine or glutamic acid [16]. The activity of this
enzyme is higher in renal cortical tubules (90%) than in the
medulla or the papilla (10% combined) [16]. Studies have also
demonstrated a net addition of L-arginine to renal venous
blood, suggesting that the L-arginine synthesized in the kidney
is not for local use but for export to extrarenal tissues [16]. It is
also known that removal of the kidneys results in a significant
accumulation of citrulline, the immediate precursor of L-argin-
me [32]. Despite a lowering of blood pressure in rats pretreated
with L-arginine before and during the period of obstruction,
renal function improved significantly in these rats, but not to
normal values. These findings suggest that changes in systemic
blood pressure are the consequences of decreased EDRF
production and that intrarenal effects of EDRF may account for
the increase in GFR and ERPF observed after unilateral release
of BUO and subsequent arginine administration.
It has been suggested that measurements of the excretion of
cyclic GMP in the urine can be a helpful tool to monitor the
production of EDRF. Some reports have shown a correlation
between the excretion of cyclic GMP in the urine and the
changes in renal hemodynamics induced by the administration
of L-arginine or its selective antagonists [28]. We found that the
urine excretion of cyclic GMP was significantly higher in rats
with BUO than in sham operated rats. These results confirm
previously reported data from our laboratory [331. We have
suggested that the higher values of cyclic GMP in the urine after
release of obstruction probably reflect the higher concentra-
tions of circulating atrial natriuretic peptide seen in rats with
bilateral ureteral ligation [33]. In the present study the excretion
of cyclic GMP in the urine was significantly greater after the
infusion of L-arginine in both sham operated rats and rats with
BUO. This finding suggests that L-arginine increases the excre-
tion of cyclic GMP in the urine presumably through the release
of EDRF. Although the values for cyclic GMP in the urine were
somewhat lower in BUO rats given an antagonist of L-arginine
(NWNAME) than in BUO rats given saline, the differences did
not achieve statistical significance. If the decrease in cyclic
GMP excretion in the urine seen after administration of
NWNAME indeed reflects the activity of EDRF, it can be
calculated that about 25% of the excretion of cyclic GMP in the
urine is EDRF-related.
Taken together our data suggest that there is a decreased
delivery of L-arginine to endothelial cells with BUO of 24 hours
duration, a model of acute renal failure, as a consequence of
either diminished synthesis of L-arginine by the kidney, or
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increased utilization by peripheral tissues. This newly de-
scribed system for control of vascular tone, EDRF, may thus be
highly dependent on renal function. Such a contention is further
supported by the data obtained in BUO rats pretreated with
L-arginine (Group 11) and with the antagonist of L-arginine
(Group 12). In the former group of rats (Group 11), treatment
with L-arginine prior to and during the period of obstruction
significantly lowered values for arterial blood pressure and
renal vascular resistance and increased GFR and ERPF, indi-
cating that administration of the substrate for EDRF synthesis
during the period of obstruction ameliorated the decrease in
renal function characteristic of this model of acute renal failure.
In the rats in which the synthesis of EDRF was inhibited prior
to obstruction (Group 12), there was no measurable renal
function after release of the obstruction. The rats of this group
were anuric after relief of BUO of 24 hours duration and their
blood pressure levels were significantly higher than those
obtained in rats with BUO given saline (Fig. 5). In pilot
experiments designed to define the dose of L-arginine to be
administered prior to and during the period of obstruction, we
found that administration of increased amounts of the substrate
can result in hypotension and a further decrease in renal
function after relief of BUO. This suggests that under condi-
tions of abundant substrate in blood the synthesis of EDRF is
not rate-limiting. It is also possible that the regulatory processes
that maintain EDRF at physiological levels under conditions of
increased arginine levels in plasma may be altered in rats with
BUO.
In summary, the results of these studies suggest that there is
a sustained basal release of EDRF under normal conditions that
modulates arterial blood pressure, renal vascular resistance,
and renal function. The EDRF system may be severely altered
after BUO of 24 hours duration. It is likely that decreased
production of EDRF during bilateral ureteral obstruction may
have a role in the decreased renal blood flow and GFR and the
sustained elevations in arterial bloo4 pressure and renal vascu-
lar resistance observed after release of obstruction.
Acknowledgments
These studies were supported by NIH NIDDK grants DK-07126,
DK-09976, and DK-40321. The assistance of Ms. Pat Verplancke and
Mr. James Havranek in the preparation of this manuscript is gratefully
acknowledged.
No reprints of this article are available.
References
1. KLAHR S, BUERKERT J, MORRISON A: Urinary tract obstruction, in
The Kidney, edited by BRENNER BM, RECTOR FC JR, Philadelphia,
Saunders, 1986, pp. 1443—1490
2. PURKER5ON ML, KLAHR S: Prior inhibition of vasoconstrictors
normalizes GFR in postobstructed kidneys. Kidney InS 35:1306—
1314, 1989
3. KLAHR S, HARRIS K, PURKERSON ML: Effect of obstruction on
renal functions. Pediatr Nephrol 2:34-42, 1988
4. REYES AA, ROBERTSON G, KLAFIR S: Role of antidiuretic hormone
in obstructive nephropathy. Proc Soc Exp Biol Med 197:49—55,
1991
5. YARGER WE, SCHOCKER DD, HARRIS RH: Obstructive nephrop-
athy in the rat: Possible roles for the renin-angiotensin system,
prostaglandins and thromboxanes in postobstructive renal function.
J Clin invest 65:400—412, 1981
6. REYES AA, KLAHR S: Role of platelet-activating factor in renal
function in normal rats and rats with obstructive nephropathy. Proc
Soc Exp Biol Med 198:572—578, 1991
7. FURCHGOTT RF, ZAWADZKI JV: The obligatory role of endothelial
cells in the relaxation of arterial smooth muscle by acetylcholine.
Nature 288:373—376, 1980
8. BOULANGER C, SCHINI V, MONCADA S, VANHOUTTE PM: Stimu-
lation of cyclic GMP production in cultured mesangial cells of the
pig by bradykinin, adenosine diphosphate, calcium ionophore
A23l87 and nitric oxide. Br J Pharmacol 101:152—156, 1990
9. PALMER RMJ, FERRIGE AS, MONCADA S: Nitric oxide accounts for
the biological activity of endothelium-derived relaxing factor. Na-
ture 327:524—526, 1987
10. PALMER RMJ, ASHTON DS, MONCADA S: Vascular endothelial
cells synthesize nitric oxide from L-arginine. Nature 333:664—666,
1988
11. BREDT DS, SNYDER S: Isolation of nitric oxide synthetase, a
calmodulin-requiring enzyme. Proc Nat! Acad Sci USA 87:682—
685, 1990
12. KONDO K, MITCHELL JA, Nucci G, VANE JR: Simultaneous
measurement of endothelium-derived relaxing factor by bioassay
and guanylate cyclase stimulation. Br J Pharmaco! 98:630—636,
1989
13. IGNARRO L, BYRNS RE, BUGA GM, WOOD KS: Endothelium-
derived relaxation factor from pulmonary artery and vein possesses
pharmacological and chemical properties identical to those of nitric
oxide radical. Cir Res 61:866—879, 1987
14. GARBERS DL: Guanylate cyclase, a cell surface receptor. J Biol
Chem 264:9103—9106, 1989
15. BoRsooK H, DUSNOFF JW: The conversion of citrulline to arginine
in the kidney. JBiol Chem 141:717—738, 1941
16. DHANAKOTI SN, BROSNAN iT, HER.ZBERG GR, BROSNAN ME:
Renal arginine synthesis: Studies in vitro and in vivo. Am J Physiol
259:E437—E422, 1990
17. WHITE RP, SAMSON FE: Determination of inulin in plasma and
urine by use of anthrone method. J Lab C!in Med 43:475—478, 1954
18. SMITH HW, FINKELSTEIN N, ALIMINOSA L, CEAWFORD B, Gi-
BElt M: The renal clearances of substituted hippuric acid derivates
and other aromatic acids in dog and man. J Clin Invest 24:388—404,
1945
19. WILKINS MR. SETTLE SL, NEEDLEMAN P: Augmentation of the
natriuretic activity of exogenous and endogenous atriopeptin in rats
by inhibition of guanosine 3',5'-cyclic monophosphate degradation.
J C!in Invest 85:1274—1279, 1990
20, KING AJ, Taov JL, DOWNES SJ, ANDERSON 5, BRENNER B:
Effects of N"-monomethyl-L-arginine (L-NMMA) on basal renal
hemodynamics and the response to aminoacid (AA) infusion.
(abstract) Kidney mt 37:371, 1990
21. BAYLIS C, HARTON F, ENGELS K: Endothelial derived relaxing
factor controls renal hemodynamics in the normal rat kidney. JAm
Soc Nephro! 1:875—881, 1990
22. O'CONNOR Wi1 SUMMERILL RA: The effect of a meal of meat on
glomerular filtration rate in dogs at normal urine flows. J Physio!
256:81—91, 1976
23. BAYLIS C, FREDERICKS M, WILSON C, MUNGER K, COLLINS R:
Renal vasodilatory response to i.v. glycine in the ageing rat kidney.
AmJKidDis 15:244—251, 1990
24. BAYLIS C: Effect of aminoacid infusion as an index of renal
vasodilatory capacity in pregnant rats. Am J Physiol 254:F650—
F656, 1988
25. PALMORE WP: Glucagon and alanine-induced increases of the
canine renal glomerular filtration rate. Q J Exp Physiol 68:319—327,
1983
26. HIR5CHBERG R, KOPPLE JD: Indomethacin blocks arginine-induced
rise of RPF and GFR in man. (abstract) Kidney mt 31:201, 1987
27. REES DD, PALMER RMJ, MONCADA S: Role of endothelium-
derived nitric oxide in the regulation of blood pressure. Proc Nat!
Acad Sci USA 86:3375—3378, 1989
28. TOLINS JP, PALMER RMJ, MONCADA S, RAIJ L: Role of endothe-
hum-derived relaxing factor in regulation of renal hemodynamic
responses. Am J Physiol 258:H655—H662, 1990
29. AISAKA K, GROSS SS, GRIFITH OW, LEVI R: N°-methylarginine,
Reyes et a!: EDRF role in obstructive uropathy 413
an inhibitor of endothelium-derived nitric oxide synthesis, is a
potent pressor agent in the guinea pig: Does nitric oxide regulate
blood pressure in vivo? Biochem Biophys Res Commun 160:881—
885, 1989
30. IsHli K, CL-SANG B, KERWIN JF Ja, HUANG Z-J, MURAD F:
NsvnitroLarginine: A potent inhibitor of endothelium-derived
relaxing factor formation. Eur J Pharmacol 176:219—223, 1990
31. ZATZ R, DE Nucci G: Effects of acute nitric oxide inhibition on rat
glomerular microcirculation. Am J Physiol 261 :F360—F363, 1991
32. WINDMUELLER HG, SPAETH AE: Source and fate of circulating
citrulline. Am J Physiol 241 :E473—E480, 1981
33. PURKERSON ML, BLAINE EH, STOKES TJ, KLAHR S:Role of atrial
peptide in the natriuresis that follows relief of obstruction in rats.
Am J Physiol 256:F583—F589, 1989
